Skip to main content

BRIEF RESEARCH REPORT article

Front. Allergy
Sec. Skin Allergy
Volume 5 - 2024 | doi: 10.3389/falgy.2024.1451296
This article is part of the Research Topic Biomarkers in Urticaria View all articles

IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria

Provisionally accepted
LUIS FELIPE ENSINA LUIS FELIPE ENSINA 1*Larissa Brandão Larissa Brandão 1L. Karla ARRUDA L. Karla ARRUDA 2Faradiba Sarquis Serpa Faradiba Sarquis Serpa 3Régis Albuquerque Campos Régis Albuquerque Campos 4Solange Rodrigues Oliveira Valle Solange Rodrigues Oliveira Valle 5Paulo Ricardo Criado Paulo Ricardo Criado 6Sarbjit Saini Sarbjit Saini 7Roberta Fachini Jardim Criado Roberta Fachini Jardim Criado 6
  • 1 ALLERGY AND IMMUNOLOGY, Federal University of São Paulo, São Paulo, Brazil
  • 2 University of São Paulo, Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil
  • 3 Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória (EMESCAM), Vitória, Espirito Santo, Brazil
  • 4 Federal University of Bahia (UFBA), Salvador, Bahia, Brazil
  • 5 Federal University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
  • 6 Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil
  • 7 Johns Hopkins Medicine, Johns Hopkins University, Baltimore, Maryland, United States

The final, formatted version of the article will be published soon.

    This multicenter study aimed to explore if baseline total IgE levels could predict omalizumab response in chronic spontaneous urticaria (CSU) patients. Refractory CSU patients, treated with omalizumab after failing second-generation H1-antihistamines, were analyzed retrospectively across seven centers in Brazil. The study assessed total IgE levels at baseline, comparing responders to non-responders, considering complete and partial responses. Results showed a significant reduction in CSU symptoms post-treatment. Non-responders had lower baseline IgE levels. A sensitivity of 67.8% and specificity of 93.3% for predicting response were found at an IgE level of 59.5 IU/ml. Similar values were observed for complete responders. Notably, a baseline IgE level lower than 59.5 IU/ml may indicate late responders. The study underscores the potential of baseline IgE levels as a predictive biomarker for omalizumab response in CSU patients. Further research, incorporating diverse populations and analyzing response variables, is warranted to validate these findings.

    Keywords: Urticaria, Immunoglobulin E, Omalizumab, biomarkers, Treatment

    Received: 19 Jun 2024; Accepted: 16 Dec 2024.

    Copyright: © 2024 ENSINA, Brandão, ARRUDA, Sarquis Serpa, Campos, Valle, Criado, Saini and Criado. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: LUIS FELIPE ENSINA, ALLERGY AND IMMUNOLOGY, Federal University of São Paulo, São Paulo, Brazil

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.